{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T04:54:52Z","timestamp":1793336092446,"version":"4.5.0"},"reference-count":14,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,1,7]],"date-time":"2025-01-07T00:00:00Z","timestamp":1736208000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,1,7]],"date-time":"2025-01-07T00:00:00Z","timestamp":1736208000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100012396","name":"Royal University Hospital Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100012396","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Psychiatry"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Ketamine is a promising therapy for treatment-resistant depression due to its rapid onset, although benefits are often transitory, with patients needing maintenance therapy to prevent relapse. Most data supporting ketamine for treatment-resistant depression refers to the intravenous route of administration, leaving alternative routes lacking in data, especially as maintenance regimens. Moreover, the safety of ketamine maintenance therapy is poorly defined. This report aims to describe and evaluate a novel hospital-to-outpatient intranasal racemic ketamine maintenance therapy program.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This was an observational program evaluation study. Participants were adult inpatients with treatment-resistant depression who had been successfully treated with intranasal racemic ketamine in hospital and were being referred for outpatient maintenance therapy with an intranasal racemic ketamine spray, administered at a specialized community treatment centre. Effectiveness was assessed with the Self-Report Quick Inventory of Depressive Symptomatology, the Quality of Life Scale, and the Clinical Global Impression-Improvement scale.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Five patients were enrolled, completing up to 14 treatment sessions over 192 days. The mean dose administered throughout treatment was 220\u00a0mg (100 to 400\u00a0mg). All patients had decreased (or stable) depressive symptoms and increased (or stable) quality of life. There were no serious adverse events or discontinuations due to adverse effects. Reported adverse effects included anxiety and nausea. Slight blood pressure increases were seen during treatment, none of which required intervention.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Intranasal racemic ketamine maintenance therapy for treatment-resistant depression appeared to be feasible and well tolerated, although effectiveness conclusions cannot be drawn from this small pilot study. Further investigations regarding the safety and effectiveness of intranasal ketamine maintenance therapy are warranted.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12888-024-06448-x","type":"journal-article","created":{"date-parts":[[2025,1,7]],"date-time":"2025-01-07T08:27:30Z","timestamp":1736238450000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Intranasal racemic ketamine maintenance therapy for patients with treatment-resistant depression: a naturalistic feasibility study"],"prefix":"10.1186","volume":"25","author":[{"given":"Katelyn","family":"Halpape","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raelle","family":"Pashovitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annabelle","family":"Wanson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monika","family":"Hooper","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evyn M.","family":"Peters","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,1,7]]},"reference":[{"key":"6448_CR1","doi-asserted-by":"crossref","unstructured":"Collins PY, Patel V, Joestl SS, March D, Insel TR, Daar AS et al. Grand challenges in global mental health. Nature [Internet]. 2011;475(7354):27\u201330. Available from: https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC3173804\/","DOI":"10.1038\/475027a"},{"issue":"1","key":"6448_CR2","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1146\/annurev-med-053013-062946","volume":"66","author":"CG Abdallah","year":"2015","unstructured":"Abdallah CG, Sanacora G, Duman RS, Krystal JH. Ketamine and Rapid-Acting antidepressants: a window into a New Neurobiology for Mood Disorder therapeutics. Annu Rev Med. 2015;66(1):509\u201323.","journal-title":"Annu Rev Med"},{"issue":"5","key":"6448_CR3","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1176\/appi.ajp.2020.20081251","volume":"178","author":"RS McIntyre","year":"2021","unstructured":"McIntyre RS, Rosenblat JD, Nemeroff CB, Sanacora G, Murrough JW, Berk M, et al. Synthesizing the evidence for ketamine and esketamine in treatment-resistant depression: an International Expert Opinion on the available evidence and implementation. AJP. 2021;178(5):383\u201399.","journal-title":"AJP"},{"key":"6448_CR4","doi-asserted-by":"publisher","first-page":"102127","DOI":"10.1016\/j.eclinm.2023.102127","volume":"62","author":"S Nikolin","year":"2023","unstructured":"Nikolin S, Rodgers A, Schwaab A, Bahji A, Zarate C, Vazquez G, et al. Ketamine for the treatment of major depression: a systematic review and meta-analysis. eClinicalMedicine. 2023;62:102127. https:\/\/doi.org\/10.1016\/j.eclinm.2023.102127.","journal-title":"eClinicalMedicine"},{"key":"6448_CR5","unstructured":"The Linden Medical Centre. Pricing. https:\/\/thelinden.ca\/?page_id=737"},{"key":"6448_CR6","unstructured":"Toronto Ketamine Clinic | IV Ketamine Treatment in Toronto and Surrounding Areas. IN Ketamine Program. Accessed September 11, 2023. https:\/\/torontoketamineclinic.com\/intranasal-ketamine-program\/"},{"key":"6448_CR7","doi-asserted-by":"publisher","first-page":"612","DOI":"10.3389\/fnhum.2016.00612","volume":"10","author":"L Li","year":"2016","unstructured":"Li L, Vlisides PE. Ketamine: 50 years of modulating the mind. Front Hum Neurosci. 2016;10:612. https:\/\/doi.org\/10.3389\/fnhum.2016.00612.","journal-title":"Front Hum Neurosci"},{"issue":"3","key":"6448_CR8","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1037\/pha0000627","volume":"31","author":"EM Peters","year":"2023","unstructured":"Peters EM, Halpape K, Cheveldae I, et al. Intranasal racemic ketamine for patients hospitalized with treatment-resistant depression: a retrospective analysis. Exp Clin Psychopharmacol. 2023;31(3):593\u20138.","journal-title":"Exp Clin Psychopharmacol"},{"issue":"5","key":"6448_CR9","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1016\/S0006-3223(02)01866-8","volume":"54","author":"AJ Rush","year":"2003","unstructured":"Rush AJ, Trivedi MH, Ibrahim HM, et al. The 16-Item Quick Inventory of Depressive Symptomatology (QIDS), clinician rating (QIDS-C), and self-report (QIDS-SR): a psychometric evaluation in patients with chronic major depression. Biol Psychiatry. 2003;54(5):573\u201383.","journal-title":"Biol Psychiatry"},{"issue":"1","key":"6448_CR10","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1477-7525-1-1","volume":"1","author":"CS Burckhardt","year":"2003","unstructured":"Burckhardt CS, Anderson KL. The quality of Life Scale (QOLS): reliability, validity, and utilization. Health Qual Life Outcomes. 2003;1(1):1\u20137.","journal-title":"Health Qual Life Outcomes"},{"issue":"7","key":"6448_CR11","first-page":"28","volume":"4","author":"J Busner","year":"2007","unstructured":"Busner J, Targum SD. The Clinical Global impressions Scale. Psychiatry (Edgmont). 2007;4(7):28\u201337.","journal-title":"Psychiatry (Edgmont)"},{"issue":"4","key":"6448_CR12","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1177\/0269881118760660","volume":"32","author":"V G\u00e1lvez","year":"2018","unstructured":"G\u00e1lvez V, Li A, Huggins C, et al. Repeated intranasal ketamine for treatment-resistant depression\u2013the way to go? Results from a pilot randomised controlled trial. J Psychopharmacol. 2018;32(4):397\u2013407.","journal-title":"J Psychopharmacol"},{"key":"6448_CR13","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1016\/j.jad.2020.07.089","volume":"276","author":"H Sakurai","year":"2020","unstructured":"Sakurai H, Jain F, Foster S, Pedrelli P, Mischoulon D, Fava M, et al. Long-term outcome in outpatients with depression treated with acute and maintenance intravenous ketamine: a retrospective chart review. J Affect Disord. 2020;276:660\u20136.","journal-title":"J Affect Disord"},{"key":"6448_CR14","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1016\/j.jad.2023.12.038","volume":"348","author":"G d\u2019Andrea","year":"2024","unstructured":"d\u2019Andrea G, Pettorruso M, Di Lorenzo G, Rhee TG, Chiappini S, Carullo R, et al. The rapid antidepressant effectiveness of repeated dose of intravenous ketamine and intranasal esketamine: a post-hoc analysis of pooled real-world data. J Affect Disord. 2024;348:314\u201322.","journal-title":"J Affect Disord"}],"container-title":["BMC Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12888-024-06448-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12888-024-06448-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12888-024-06448-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,7]],"date-time":"2025-01-07T21:04:42Z","timestamp":1736283882000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcpsychiatry.biomedcentral.com\/articles\/10.1186\/s12888-024-06448-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,7]]},"references-count":14,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["6448"],"URL":"https:\/\/doi.org\/10.1186\/s12888-024-06448-x","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-4125617\/v1","asserted-by":"object"}]},"ISSN":["1471-244X"],"issn-type":[{"value":"1471-244X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,7]]},"assertion":[{"value":"18 March 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 December 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 January 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Dr. Monika Hooper has received speaker honoraria from the Canadian Collaborative Research Network, Lundbeck, and Otsuka. She is also co-owner of the Linden Medical Centre. Katelyn Halpape receives an honorarium for ongoing work as a chapter editor for the Clinical Handbook of Psychotropic Drugs. The other authors have no conflicts to declare.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"23"}}